Abstract: Modified cells comprising a transmembrane polypeptide comprising at least one extracellular target receptor-binding domain, a transmembrane domain and an intracellular domain, wherein the intracellular domain is not capable of transducing any signal are provided. Methods of inducing or inhibiting signaling by a target receptor in a target cell comprising contacting the target cell with a modified cell of the invention are also provided.

Abstract: The present disclosure provides CpG oligodeoxynucleotides (ODNs) as immunogenic molecules, and their use in methods of initiating or promoting innate or adaptive immunity in fish or increasing an immune response against an antigen in fish.

Abstract: A polynucleotide is provided. The polynucleotide encoding a chimeric polypeptide comprising an amino acid sequence of an immune checkpoint molecule capable of binding a ligand thereof, the immune checkpoint molecule being translationally fused to another amino acid sequence of a cell signaling module such that upon binding of the immune checkpoint molecule to the ligand, the cell signaling module is activated. Also provided other configurations of the polynucleotide, cells comprising the polynucleotides and methods of using the cells expressing the polynucleotides.

Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.

Abstract: A Tumor Micro-Environment (TME) responsive expression vector including a nucleic acid sequence of a synthetic promoter, comprising two or more promoter-response-elements inducing expression of an immune-effector gene.

Abstract: Methods of increasing regulatory T cells in a subject by administering an IL-2 chimeric molecule with increased serum half-life as compared to wild-type Il-2 are provided. Methods of treating inflammatory and autoimmune disease are also provided.

Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.

Abstract: A Tumor Micro-Environment (TME) responsive expression vector including a nucleic acid sequence encoding a synthetic promoter comprising one or more promoter-response-elements, and a nucleic acid sequence encoding immune-effector genes, such as chimeric antigen receptor. The TME responsive vector is designed to induce the expression of immune-effector genes within TME, and not in normal healthy tissues, thus focusing immune activities, increasing safety and reducing the ON-target OFF-tumor hazard.

Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.

Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.

Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: Modified cells comprising a transmembrane polypeptide comprising at least one extracellular target receptor-binding domain, a transmembrane domain and an intracellular domain, wherein said intracellular domain is not capable of transducing any signal are provided. Methods of inducing or inhibiting signaling by a target receptor in a target cell comprising contacting the target cell with a modified cell of the invention are also provided.

Abstract: The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.

Abstract: Specific peptides derived from the cytotoxicity receptor natural killer protein 44 (NKp44) useful for treating diseases such as cancer are described. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.

Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.

Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Abstract: The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.